Abstract: Method for producing multiply-charged helium nanodroplets and charged dopant clusters and nanoparticles out of the helium nanodroplets, the method comprising: •producing neutral helium nanodroplets in a cold head (1) via expansion of a pressurized, pre-cooled, supersonic helium beam of high purity through a nozzle (3) into high vacuum with a base pressure under operation preferably below 20 mPa, •ionizing the helium nanodroplets by electron impact (15), wherein the electron impact (15) leads to multiply-charged helium nanodroplets, •doping the charged helium nanodroplets with dopant vapor in the pickup cell (19), wherein the doped nanodroplets form cluster ions with the initial charges acting as seeds, wherein the size of the nanoparticles can vary from a few atoms up to 105 atoms by arranging the size of the neutral helium nanodroplets, the charge of the helium nanodroplets and the density of dopant vapor in the pickup cell (19).

Abstract: The present invention provides valuable peptidomimetics for therapeutic and diagnostic purposes as well as compositions, methods, uses and kits based on these peptidomimetics. In particular, the peptidomimetics of the present invention are incorporated by CCK2R expressing cells, for instance, cancer cells. This allows, for instance, to selectively destroy cancer cells or to selectively image cancer cells that express CCK2R.

Abstract: The present invention relates to a reflector for an acoustic shock or pressure wave head, wherein the reflector comprises an acoustically reflective surface formed by a body of rotation, said body of rotation being formed by rotation of an elliptical segment about a rotation axis which extends through a focal point of the ellipse and encloses an angle ? between 0.1° and 30° with the main axis of the ellipse.

Abstract: The present invention relates to a single-use test-strip for the quantitative determination of sodium concentration and creatinine concentration and for the subsequent determination of their ratio, and to a non-invasive point-of-care (POC) device for detecting sodium depletion and/or sodium overload in a patient's body. Furthermore, the present invention relates to a method for simultaneously and quantitatively determining sodium concentration and creatinine concentration in a patient's urine sample and to a method of detecting sodium depletion and/or sodium overload in a patient's body.

Abstract: The present invention relates to a method of site-directed integration into a genetic locus encoding at least one activity of the pyrimidine salvage pathway in a host cell, wherein said activity of the pyrimidine salvage pathway is purine/cytosine permease (FcyB), cytosine deaminase (FcyA), uracil-phosphoribosyl-transferase (Uprt), concentrative nucleoside transporter (CntA) or uridine kinase (UK), comprising: a) providing a host cell comprising a functional copy of the genetic locus encoding at least one activity of the pyrimidine salvage pathway; (b) introducing a gene or sequence of interest into said host cell via transformation of an integrative nucleic acid construct which comprises 3? and/or 5? of the gene or sequence of interest flanks being homologous to said genetic locus or which carries a sequence being homologous to said genetic locus of the pyrimidine salvage pathway and thus allowing for a homologous recombination at said genetic locus, wherein said homologous recombination is capable of causin

Abstract: The present invention relates to a reflector for an acoustic shock or pressure wave head, wherein the reflector comprises an acoustically reflective surface formed by a body of rotation, said body of rotation being formed by rotation of an elliptical segment about a rotation axis which extends through a focal point of the ellipse and encloses an angle ? between 0.1° and 30° with the main axis of the ellipse.

Abstract: The present invention relates to 3-amino-pyrazolo[3,4-d]pyrimidin-4-ones, such as for example, N-{4-[1-(2,6-dichloro-4-sulfamoyl-phenyl)-3-dimethylamino-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-ylmethyl]-phenyl}-2-diethylamino-acetamide, particularly useful as cyclin dependent kinase (CDK) inhibitors, pharmaceutical compositions comprising the same and the use thereof in particular in the prophylaxis and/or treatment of cancer and other proliferative diseases. Furthermore, the present invention relates to processes for the synthesis of said 3-aminopyrazolo[3,4d]pyrimidin-4-ones and intermediates to be used in the processes of the present invention.

Abstract: The present disclosure relates to an intraoral suctioning device for intraoral negative pressure wound treatment and a method for manufacturing the same. In order to permanently maintain the negative pressure in a wound with a view to an improved wound treatment and regeneration process, the intraoral suctioning device for the intraoral negative pressure wound treatment as disclosed can include a dental splint, an elastic membrane sealing an aperture formed in the dental splint so as to define a sealed wound treatment area on the inside of the dental splint, and a suctioning channel system for evacuating the wound treatment area.

Abstract: A registration device for patient registration comprises at least one reference marker adapted to be sensed by an imaging system and/or at least one position element adapted to be localized by a position sensing system, and fixation element for positioning the registration device in a patient's body cavity at a location comprising soft tissue. The registration device is adapted to be introduced into and positioned in the patient's body cavity, particularly in the viscerocranium such as the nasal cavity, the nasopharynx, the ear canal(s) and/or the neurocranium such as a cerebral ventricle.

Abstract: The present disclosure relates to an intraoral suctioning device for intraoral negative pressure wound treatment and a method for manufacturing the same. In order to permanently maintain the negative pressure in a wound with a view to an improved wound treatment and regeneration process, the intraoral suctioning device for the intraoral negative pressure wound treatment as disclosed can include a dental splint, an elastic membrane sealing an aperture formed in the dental splint so as to define a sealed wound treatment area on the inside of the dental splint, and a suctioning channel system for evacuating the wound treatment area.

Abstract: The present invention relates to compounds of formula (III) or to compounds of formula (IV) wherein R1, R2, R3 and R4 are as defined in the claims, and their use in therapeutic treatments of 5-lipoxygenase related diseases such as chronic airway inflammatory or dermatological disorders.

Abstract: A connection system for connecting a timber component to a building element, comprising a first holding section for the building element, a second holding section for the timber component, a coupling element which releasably connects the first holding section and the second holding section, wherein the second holding section comprises (i) a timber-component-side fitting having a first contact surface for attachment to a first surface of the timber component, and (ii) a second contact surface for a second surface of the timber component, wherein the first contact surface of the timber-component-side fitting and the second contact surface of the second holding section together enclose an angle (?) other than 180°.

Abstract: A method and apparatus for chemical ionization of analyte gas particles in a carrier gas by introducing primary ions, characterized in that the primary and product ions are accelerated by a rotating electric field orthogonal to that direction (5) in which the ions are transported towards the exit (3) of the reaction volume (1). This can, for example, reduce unwanted cluster formation without increasing the transport speed of the ions through the reaction chamber, which improves, for example, the product ion yield. The apparatus of the invention achieves this by means of N?3 rod electrodes (6) to which N AC voltages U1(t), . . . , UN(t) with N different phase positions ascending in one sense of rotation ?1, . . . , ?N are applied.

Abstract: The present invention relates to a predictive diagnostic method for identifying whether a patient will develop metabolic syndrome and/or type-2 diabetes in the future. In particular, the invention relates to a method for identifying a subject which has a risk for developing metabolic syndrome and/or type-2 diabetes, wherein the method comprises (a) analyzing (i.e. determining/measuring/quantifying) in a sample obtained from a test subject the amount of miR-122; and (b) identifying (i.e. detecting) a subject, which has a risk for developing metabolic syndrome and/or type-2 diabetes, wherein an increased amount of miR-122 as compared to the amount of miR-122 of a healthy reference population indicates a risk for developing metabolic syndrome and/or type-2 diabetes. Another aspect of the invention relates to a method for monitoring the therapeutic success during the treatment of metabolic syndrome and/or type-2 diabetes, wherein the method comprises (a) analyzing (i.e.

Abstract: A compound of formula (II), and a method of preparation thereof, for use as a smooth muscle cell (SMC) proliferation-inhibiting drug: wherein: R1 to R6 are —H, —F, —CH3, —CF3, —CF2CH3, —OCH3, —COCH3, —C4H9, —COOC2H5, or —C6H5, or two vicinal residues from R1 to R6 form a saturated or unsaturated carbocyclic ring together with the two carbon atoms to which they are attached; R7 is OH, allyloxy, propargyl-oxy, 2,2-dimethylpropanoyloxy (pivaloyloxy), butanoyloxy, 3-methylbutanoyloxy, 2-buten-oyloxy, 2-methyl-2-butenoyloxy, 3-methyl-2-butenoyloxy, isopentanoyloxy, 2-ethylbutanoyl-oxy, 3,3-dimethylbutanoyloxy, cyclopropylcarbonyloxy, cyclobutylcarbonyloxy, cyclo-pentylcarbonyloxy, cyclopentenylcarbonyloxy, cyclohexylcarbonyloxy, cyclo-hexenylcarbonyloxy, adamantylethanoyloxy, 3-phenylpropenoyloxy (cinnamyloyloxy), 2-methylbenzoyloxy, or naphthoyloxy; wherein, in ring A and/or B, one or more carbon ring atoms are optionally replaced by heteroatoms; wherein the compounds of formula (II) are obtained by combining

Abstract: The present invention relates to a pharmaceutical composition comprising specific compounds which may be obtained from Leontopodium alpinum Cass. (Edelweiss). A preferred compound is leoligin (=(2S,3R,4R)-4-(3,4-dimethoxybenzyl)-2-(3,4-dimethoxyphenyl)tetrahydrofuran-3-yl]methyl(2Z)-2-methylbut-2-enoat]). Corresponding means and methods in respect of medical uses of the compounds are described. The present invention also provides a medical device comprising, containing or having been contacted with the compound. The compounds provided herein may particularly be used in the treatment of hyperplastic diseases, in particular intimal hyperplasia, e.g. stenosis, restenosis, atherosclerosis and the like. Also envisaged herein is the use of these compounds in the treatment of proliferative diseases, such as leukemia, prostate cancer and lung cancer.

Abstract: The present invention relates to a hydraulic energy store (1) having a first (2) and a second fluid reservoir (6), the fluid levels (4, 12) of which extend at different heights, which are connected to one another via a turbine/pump arrangement (10) and during the operation of which a fluid (3) can be moved to and fro between the first (2) and second fluid reservoir (6) and energy can be converted in the process. The second fluid reservoir (6) is configured as a container which is arranged within the fluid (3) in the first fluid reservoir (2), wherein, during operation, the fluid level (12) in the second fluid reservoir (6) can be changed in such a way that, as a result, the immersion depth (ht) of said second fluid reservoir (6) in the first fluid reservoir (2) can be changed owing to buoyancy.

Abstract: Electrochemical cell array for the treatment of a sample via electro-(end-)osmotic flow, comprising (i) an electrode chamber, comprising a cathodic compartment (CC) and an anodic compartment (AC), (ii) a cathode (C), being arranged in the cathodic compartment (CC), (iii) an anode (A), being arranged in the anodic compartment (AC), (iv) an intermediate cathodic compartment (C1) (v) an intermediate anodic compartment (A1) (iv) a first selective membrane (M1) being arranged between said cathodic compartment (CC) and said first intermediate cathodic compartment (C1) (v) a second selective membrane (M2) being arranged between said anodic compartment (AC) and said first intermediate anodic compartment (A1) (vi) a treatment compartment (T) for the sample being arranged between said intermediate cathodic compartment (C1) and said intermediate anodic compartment (A1), further comprising a first separator membrane (S1) between said treatment compartment (T) and said intermediate cathodic compartment (C1) and a secon

Abstract: The present invention relates to novel peptidic inhibitors of signal transmission from G?s- to G?i-coupled receptor cascades and methods for their use.

Abstract: The present invention relates to a pharmaceutical composition comprising specific compounds which may be obtained from Leontopodium alpinum Cass. (Edelweiss). A preferred compound is leoligin (=(2S,3R,4R)-4-(3,4-dimethoxybenzyl)-2-(3,4-dimethoxyphenyl)tetrahydrofuran-3-yl]methyl(2Z)-2-methylbut-2-enoat]). Corresponding means and methods in respect of medical uses of the compounds are described. The present invention also provides a medical device comprising, containing or having been contacted with the compound. The compounds provided herein may particularly be used in the treatment of hyperplastic diseases, in particular intimal hyperplasia, e.g. stenosis, restenosis, atherosclerosis and the like. Also envisaged herein is the use of these compounds in the treatment of proliferative diseases, such as leukemia, prostate cancer and lung cancer.